No Data
No Data
Hisun Pharmaceutical's Veterinary Arm Gets Registration Certificate for Mirtazapine Ointment
Zhejiang Hisun Pharmaceutical's (SHA:600267) unit, Zhejiang Hisun Animal Health Products, received approval from China's Ministry of Agriculture and Rural Affairs to register an ointment for cats
Zhejiang Hisun Pharmaceutical (600267.SH): The injection of Teicoplanin has passed the consistency evaluation of quality and efficacy of generic drugs.
On July 11th, Gelonhui reported that Zhejiang Hisun Pharmaceutical Co., Ltd. (600267.SH) received an approved and issued notification of supplementary drug application approval for injectable telavancin from the National Medical Products Administration. The company's injectable telavancin has passed the consistency evaluation of generic drug quality and efficacy. Injectable telavancin is used to treat various severe Gram-positive bacterial infections, including those that cannot be treated with penicillin or cephalosporin antibiotics; severe Staphylococcus aureus infections that cannot be treated with penicillin or cephalosporin antibiotics or have failed treatment with the above antibiotics; or Staphylococcus aureus infections resistant to other antibiotics. It has been proven effective.
Zhejiang Hisun Pharmaceutical (600267.SH): Its subsidiary received the "Approval Notice for Listing Application for Chemical Raw Materials" for its supply of active pharmaceutical ingredient of Efavirenz.
On July 10th, Gelunhui reported that Zhejiang Hisun Pharmaceutical(600267.SH) announced that its wholly-owned subsidiary, Hisun Pharmaceutical (Hangzhou) Co., Ltd. (referred to as "Hisun Hangzhou Company") received the "Chemical Raw Materials Application Approval Notice for Ivosidenib Raw Materials" issued and approved by the National Drug Administration. Ivosidenib is used for adult patients with advanced renal cell carcinoma who have failed previous treatment with sunitinib or sorafenib. It is also used for adult patients with unresectable, locally advanced or metastatic, well-differentiated (moderately or highly differentiated) progressing pancreatic neuroendocrine tumors and for those who cannot undergo surgical resection.
Hisun Pharmaceutical's Leukemia Drug Gets Marketing Approval
Zhejiang Hisun Pharmaceutical's (SHA:600267) cytarabine for injection obtained a drug registration certificate from China's National Medical Products Administration, according to the company's disclos
Zhejiang Hisun Pharmaceutical (600267.SH): The injection of acyclovir has obtained a drug registration certificate.
On June 26th, Gelunhui announced that its wholly-owned subsidiary, Hanhui Pharmaceuticals Co., Ltd., recently received the injection of Arabinofuranosyl Cytidine 《Pharmaceutical Registration Certificate》 issued by the National Medical Products Administration. Injection of Arabinofuranosyl Cytidine is mainly used for inducing and maintaining remission of acute non-lymphocytic leukemia in adults and children. The original manufacturer is Pfizer.
Zhejiang Hisun Pharmaceutical (600267.SH): Injection of levofloxacin hydrochloride passes generic drug consistency evaluation.
On June 26th, Gelonghui reported that Zhejiang Hisun Pharmaceutical (600267.SH) announced that its wholly-owned subsidiary, Hanhui Pharmaceutical Co., Ltd. (referred to as "Hanhui Pharmaceutical"), has received the injection of idarubicin hydrochloride approved supplement application approval notice issued by the State Drug Administration. Hanhui Pharmaceutical's drug injection of idarubicin hydrochloride has passed the consistency evaluation of generic drug quality and efficacy. Injection of idarubicin hydrochloride is suitable for adult induction remission of acute non-lymphocytic leukemia (ANLL) without previous treatment and induction remission of adult relapsed and refractory ANLL, as well as acute lymphoblastic leukemia for adults and children.
No Data